BUZZ-Corcept drops after US FDA declines to approve drug for rare hormonal disorder
Reuters
Dec 31, 2025
BUZZ-Corcept drops after US FDA declines to approve drug for rare hormonal disorder
** Shares of drugmaker Corcept TherapeuticsCORT.O fall 38.7% to $48.39 premarket
** CORT says U.S. FDA has declined to approve its hormone-blocking oral therapy, relacorilant, for the treatment of a rare hormonal disorder
** FDA says "it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness" - CORT
** Co was testing relacorilant to treat Cushing's syndrome, also known as hypercortisolism, which occurs when the body is exposed to high cortisol activity
** As of last close, stock up 39.3% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.